World Health Day, observed annually on April 7th, provides an opportunity to focus on key public health issues. This date also commemorates the founding anniversary of the World Health Organization (WHO) in 1948. The theme for World Health Day 2024 is 'My health, my right', which underscores the significance of individual health empowerment.
Meanwhile, the month of March saw several notable milestones with regards to FDA approvals.
On Mar.21, 2024, the FDA approved Italfarmaco's Duvyzat, which marks the first nonsteroidal drug to treat patients with all genetic variants of Duchenne Muscular Dystrophy (DMD).
The first gene therapy for children with metachromatic leukodystrophy, Lenmeldy, developed by Orchard Therapeutics was greenlighted by the U.S. regulatory agency on Mar.18, 2024.
On Mar.14, 2024, Madrigal Pharma's Rezdiffra received the FDA nod, becoming the first treatment for adults with noncirrhotic NASH (also called MASH).
Now, let's take a look at the biotech stocks awaiting FDA decision in April 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.